Let's think about how to develop health R&I in the Danube Strategy

1. Transregional Network for Innovation and Technology Transfer to Improve Health Care
Rete transregionale per l’innovazione ed il trasferimento tecnologico per il miglioramento della sanità
Transregionalno omrežje za inovacijo in prenos tehnološkega znanja za izboljšanje zdravstva
Suggestions for:
Exploitation of synergies, common
actions and new project ideas for Danube
RIS3 – priority HEALTH
Sabina Passamonti
University of Trieste, Lead Partner
Danube S3 Workshop: “Gathering opportunities
around RIS3 priorities”
at Austrian Federal Ministry of Science, Research and
Economy, Freyung 3, 1014 Vienna
07.07.2015

2. What is the Danube S3 Workshop?
See below or read more in
http://s3platform.jrc.ec.europa.eu/s3-in-danube-vienna-2015

3. Thematic discussion group
Health
“The workshop participants were divided in the smaller
thematic discussion groups on ICT, health, energy and
sustainable innovation where 16 new project ideas
were explored to start collaboration in S3 priorities.”
All other project ideas are available in:
http://s3platform.jrc.ec.europa.eu/s3-in-danube-vienna-2015
Trans2Care project ideas and collaboration areas
are presented here.

4. What future for Trans2Care?
• Replication? (we again …)
• Imitation? (the others … here and elsewhere)
• Transposition? (the others … elsewhere)
• Evolution? (another thing…)

5. What future for Trans2Care?
- some answers
• Replication
– No, Trans2Care is not perfect; many pitfalls.
• Imitation
– We do not recommend; pitfalls2 (no experience x
pitfalls imitation)
• Transposition
– Careful: there are regional specificities
• Evolution
– We recommend à amplification of opportunities

6. How to evolve?
GENERAL OBJECTIVE
Improve the capacity to push research
results into innovation

7. ACTIONS NEEDED
1. Refinement and development of the
strategic core of Trans2Care
• More solutions to closely link research with
innovation
2. More efficient and coordinated
thematic research activities
• More results that can be directly taken up
by hospitals, care services, SMEs, schools
and public authorities

8. PRODUCTS
tools,
guidelines,
advices,
networking,
…
Trans2Care natural evolution in
INTERREG Programmes
CORE
STRATEGIC
PROJECT
developing
solu-ons
for
linking
biomedical
research
results
with
innova-on
RESULTS
Efficient
R&I
by
thema5c
projects
NeurodegeneraBve
diseaeses
Cancer
diseaeses
Cardiovascular
diseaeses
Airways
and
pulmonary
diseaeses
Metabolic
diseaeses
SUPPORT
FOR
&
IMITATION
BY
FOCUSSED,
THEMATIC
PROJECTS
BIG
LP
EFFORT
CAPITALISATION
WITH
Pacinno
project
(IPA-­‐
Adria-c
2007-­‐2013)
RegHealth-­‐RI
project
(Horizon
2020)

9. TARGET
3
Quality
of
research-­‐industry
interplay
Currently under evalutation
TARGET
2
Quality
of
insBtuBons
TARGET
1
Quality
of
human
capital
OUTPUTS
TRAINING
TOOLS
ACTION
PLANS
STRATEGY
PAPERS
RESULTS
Biomedical
researchers
at
ease
both
in
the
lab
and
with
entrepresises
and
public
authoriBes.
CreaBve
relaBonships

10. Why this special evolution?
Let some figures speak by themselves.
Look at our survey results.

11. Our simple survey
• Title: “Survey on joint applications to Interreg and
Horizon 2020 programmes-Health Topics”
• 10 Questions
• Sent to ca. 300 persons:
– Registered attendees of former Italy-Slovenia Cross-border
Biomedical Conference (27.02.2014)
(http://www.trans2care.eu/Sections.aspx?section=510.595)
– Professors and post-doc fellows of Dept. of Life Sciences
– Trans2Care Partners
• Open 30.06.2015-06.07.2015
• 52 RESPONDENTS

12. The 10 questions of the survey
1. Can you list some key words describing your research expertise?
2. How would you describe your availability of research staff?
3. How would you describe the size of your grants?
4. What kind of funds do you usually get for your research?
5. What are your research objectives?
6. How severe is your shortage of funds?
7. Are you short of research staff?
8. Are you short of administration support?
9. How do you bypass the factors (funds, research and administrative
staff) that challenge your research?
10. What role do you prefer in a collaborative project?

13. DATA ANALYSIS

14. RESEARCH EXPERTISE

15. 19,61%&
15,69%&
11,76%&
37,25%&
19,61%&
0%& 5%& 10%& 15%& 20%& 25%& 30%& 35%& 40%&
I&have&no&staff,&I&work&alone&
I&have&only&pre=graduate&students&
I&have&only&PhD&student(s)&
I&have&a&non=permanent&research&team&
(PhDs&and&post=docs)&
I&have&a&stable&research&team&
My#research#staff#
Funds and human capital
baseline
30,00%%
44,00%%
16,00%%
14,00%%
0,00%%
0%% 5%% 10%%15%%20%%25%%30%%35%%40%%45%%50%%
None%
Small%grants%(ca.%20.000%€/year)%
Medium%grants%(ca.%80.000%€/year)%
Large%grants%(ca.160.000%€/year)%
I%have%no%needs%for%the%next%3%years%
My#usual#research#grants#

16. 0,00%$
10,00%$
20,00%$
30,00%$
40,00%$
50,00%$
60,00%$
never$(0%
)$
seldom
$(<30%
)$
o7en$(>70%
)$
m
ixed$(30<50%
)$
alw
ays$(100%
)$
Percent'of'answers'
The'kinds'of'my'grants'
public$compeDDve$
private$compeDDve$
contracts$with$public$
bodies$
contracts$with$private$
bodies$

17. RESEARCH OBJECTIVES

18. 8,51%&
12,77%&
31,91%&
40,43%&
4,26%&
0%& 10%& 20%& 30%& 40%&
absent&
I&have&mild&shortage,&but&no&research&ac@vi@es&disrup@on&
I&have&shortage,&but&I&compensate&with&collabora@ons&
I&have&severe&shortage,&so&I&must&limit&my&research&
poten@al&
very&severe,&so&I&cannot&do&experimental&research&alone&
or&in&collabora@on&
How$severe$is$your$shortage$of$funds?$
RESEARCH CHALLENGES

19. 9,09%%
15,91%%
18,18%%
56,82%%
4,55%%
0%% 10%% 20%% 30%% 40%% 50%% 60%%
I%have%no%needs%(I%have%staff)–%
I%need%one%PhD%fellow–%
I%need%one%postAdoc%fellow–%
I%need%one%PhD%and%one%postAdoc%fellow–%
I%need%2%postAdoc%fellows–%
How$much$staff$do$you$need?$
14,58%'
41,67%'
8,33%'
18,75%'
10,42%'
0%' 10%' 20%' 30%' 40%' 50%'
No'shortage'
Mild'shortage'(I'compensate'by'doing'some'
administraBve'work)''
Medium'shortage'(I'compensate'by'external'support)'
Severe'shortage'(I'must'limit'my'research'grant'
applicaBon'potenBal)'
Very'severe'(I'cannot'be'Lead'Partner)'
Are$you$short$of$administra1ve$support?$

20. 0,00%$
0,00%$
21,74%$
50,00%$
30,43%$
0%$ 10%$ 20%$ 30%$ 40%$ 50%$
never$
preferably$not$
rarely$
o7en$
always$
How$do$you$bypass$the$factors$(funds,$research$
and$administra7ve$staff)$that$challenge$your$
research?$
BY$COLLABORATIONS$
0%#
10%#
20%#
30%#
40%#
50%#
absolutely#no#preferably#no#
neutral#preferably#yes#absolutely#yes#
0,00%# 2,22%#
28,89%#
35,56%#
33,33%#
0,00%# 2,33%#
11,63%#
48,84%#
37,21%#
Do#you#like#to#be#a#Project#Partner?#
In#a#small#project#
(3@5#Partners)#
In#a#large#project#
(8@12#Partners)#
0%#
10%#
20%#
30%#
40%#
50%#
absolutely#no#
preferably#no#
neutral#
preferably#yes#
absolutely#yes#
9,09%#
20,45%#
43,18%#
18,18%#
9,09%#
21,43%#
47,62%#
21,43%#
4,76%# 4,76%#
Do#you#like#to#be#the#Lead#partner?#
In#a#small#project#
(3@5#Partners)#
In#a#large#project#
(8@12#Partners)#

21. Considerations
This could be steered by the Interreg
Programme Authorities:
• The projects calls could be clear in defining not
only WHAT is the ultimate goal of a given
Programme but also HOW.
– comprehensive strategic projects can support the the
thematic projects.
– some strategic projects could be quite complementary
to some tasks of the Technical Secretariats
– thematic projects (rather than the strategic ones) are
definitely more fitting than strategic ones to our
biomedical research community.

22. Transregional Network for Innovation and Technology Transfer to Improve Health Care
Rete transregionale per l’innovazione ed il trasferimento tecnologico per il miglioramento della sanità
Transregionalno omrežje za inovacijo in prenos tehnološkega znanja za izboljšanje zdravstva
ProgeSo
Rete
Transregionale
per
l’innovazione
ed
il
Trasferimento
Tecnologico
per
il
Miglioramento
della
Sanità
finanziato
nell’ambito
del
Programma
per
la
Cooperazione
Transfrontaliera
Italia-­‐Slovenia
2007-­‐2013,
dal
Fondo
europeo
di
sviluppo
regionale
e
dai
fondi
nazionali.
Projekt
Transregionalno
omrežje
za
inovacijo
in
prenos
tehnološkega
znanja
za
izboljšanje
zdravstva
sofinancirana
v
okviru
Programa
čezmejnega
sodelovanja
Slovenija-­‐Italija
2007-­‐2013
iz
sredstev
Evropskega
sklada
za
regionalni
razvoj
in
nacionalnih
sredstev.
Thank you for your attention
Partners:
LP
–
Università
degli
Studi
di
Trieste,
PP1
–
Kemijski
InšBtut
Ljubljana,
PP1
–
Kemijski
InšBtut
Ljubljana,
PP2
–
Scuola
Internazionale
Superiore
di
Studi
AvanzaB,
PP3
–
Univerza
v
Novi
Gorici,
PP4
–
Università
di
Ferrara,
PP5
–
Treviso
Tecnologia,
PP6
–
Splošna
Bolnišnica
Dr.
Franca
Derganca,
PP7
–
Università
Ca’
Foscari
di
Venezia,
PP8
–
Università
di
Udine,
PP9
–
IRCCS
Burlo
Garofalo,
PP10
–
Zavod
Republike
Slovenije
Za
Transfuzijsko
Medicino,
PP11
–
Ortopedska
Bolnišnica
Valdoltra,
PP12
–
Univerza
na
Primorskem
-­‐
Fakulteta
za
Vede
o
Zdravju.
!
Sabina Passamonti, MD, PhD
University of Trieste
spassamonti@units.it
+393665898629